The majority of gastrointestinal stromal tumors (GIST) harbor an activating mutation in either the KIT or PDGFRA receptor tyrosine kinases. Approval of imatinib. a KIT/PDGFRA tyrosine kinase inhibitor (TKI). meaningfully improved the treatment of advanced GIST. https://www.lodiceelpueblo.com/product-category/support/